TVGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGNW

Tevogen Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$6.77−0.30 (-4.24%)

Close on Oct 19, 2026

Market cap: $25.92M
P/E (TTM): –
Dividend yield: –

Tevogen Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Stock-Based Compensation	16	41	–	–
Change in Accounts Payable	-1.96	1.69	1.11	0.17
Operating Cash Flow	-12	-12	-8.17	-0.22
Capital Expenditures	-0.06	–	-0.13	–
Investing Cash Flow	-0.06	–	-0.13	–
Share Repurchases	–	–	-343	–
Financing Cash Flow	12	12	3.87	–
Net Change in Cash	-0.73	0.23	-4.43	–
Free Cash Flow	-12	–	-8.30	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 352.5%

Financial strength

Current ratio: 0.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 17.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –